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Maternal body mass index (BMI) is associated with increased birth weight but does not explain all the 
variance in fetal adiposity. Objective 
To assess the contribution of maternal body fat distribution to offspring birth weight and adiposity. 
Design 
Longitudinal study throughout gestation and at delivery. Setting 
Women recruited at 12 weeks of gestation and followed up at 26 and 36 weeks. Cord blood was collected 
at delivery. Patients 
Pregnant women (n = 45) with BMI 18.0 to 46.3 kg/m2 and healthy pregnancy outcome. Methods 
Maternal first trimester abdominal subcutaneous and visceral adipose tissue thickness (SAT and VAT) 
was assessed by ultrasound. Main Outcome Measures 
Maternal body fat distribution, maternal and cord plasma glucose and lipid concentrations, placental 
weight, birth weight, and fetal adiposity assessed by cord blood leptin. Results 
VAT was the only anthropometric measure independently associated with birth weight centile (r2 adjusted 
15.8%, P = .002). BMI was associated with trimester 2 and trimesters 1 through 3 area under the curve 
(AUC) glucose and insulin resistance (Homeostatic Model Assessment). SAT alone predicted trimester 2 
lipoprotein lipase (LPL) mass (a marker of adipocyte insulin sensitivity) (11.3%, P = .017). VAT was 
associated with fetal triglyceride (9.3%, P = .047). Placental weight was the only independent predictor of 
fetal adiposity (48%, P < .001). Maternal trimester 2 and AUC LPL were inversely associated with fetal 
adiposity (r = -0.69, P = .001 and r = -0.58, P = .006, respectively). Conclusions 
Maternal VAT provides additional information to BMI for prediction of birth weight. VAT may be a marker 
of reduced SAT expansion and increased availability of maternal fatty acids for placental transport. 
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Abstract 
Context Maternal body mass index (BMI) is associated with increased birth weight 
but does not explain all the variance in fetal adiposity.  
Objective To assess the contribution of maternal body fat distribution to offspring 
birth weight and adiposity.  
Design Longitudinal study throughout gestation and at delivery. 
Setting Women recruited at 12 weeks of gestation and followed up at 26 and 36 
weeks. Cord blood was collected at delivery. 
Patients Pregnant women (n=45) with BMI 18.0-46.3 kg/m2 and healthy pregnancy 
outcome.  
Methods Maternal first trimester abdominal subcutaneous and visceral adipose 
tissue thickness (SAT and VAT) was assessed by ultrasound.  
Main outcome measures Maternal body fat distribution, maternal and cord plasma 
glucose and lipid concentrations, placental weight, birth weight and fetal adiposity 
assessed by cord blood leptin. 
Results VAT was the only anthropometric measure independently associated with 
birth weight centile (r2 adjusted 15.8%, P=0.002). BMI was associated with trimester 
2 and trimester 1 – 3 area under the curve (AUC) glucose and insulin resistance 
(HOMA).  SAT alone predicted trimester 2 lipoprotein lipase (LPL) mass (a marker of 
adipocyte insulin sensitivity) (11.3%, P=0.017). VAT was associated with fetal 
triglyceride (9.3%, P=0.047).  Placental weight was the only independent predictor of 
fetal adiposity (48%, P<0.001). Maternal trimester 2 and AUC LPL were inversely 
associated with fetal adiposity (r=-0.69, P=0.001 and r=-0.58, P=0.006 respectively).  
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Conclusions Maternal VAT provides additional information to BMI for prediction of 
birth weight. VAT may be a marker of reduced SAT expansion and increased 
availability of maternal fatty acids for placental transport.  
Precis 
In pregnant women with a healthy pregnancy outcome, first trimester visceral 
adipose tissue predicted birthweight centile possibly due to increased delivery of 
fatty acids to the placenta. 
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Introduction 
Maternal obesity occurs in around 20% of the UK antenatal population (1) and is 
associated with an increased risk of adverse pregnancy outcome (2) including the 
metabolic diseases of pregnancy, gestational diabetes mellitus (GDM) and pre-
eclampsia. Maternal obesity is also associated with offspring obesity, both at birth 
and in later life (3). Studies show that maternal pre-pregnancy total body fat predicts 
birth weight, though it is unclear to what extent this is explained by fetal somatic 
growth or fetal accumulation of fat (4). There is increasing concern about the impact 
of maternal BMI on the long term metabolic health of the fetus (5). 
Maternal obesity is associated with maternal insulin resistance (6) and metabolic 
dysfunction (7,8). GDM is defined by maternal hyperglycaemia and the associated 
fetal macrosomia may be explained by increased placental transport of glucose 
leading to increased fetal insulin secretion and hence increased growth, as described 
by Pedersen (9). This observation has now been extended to glucose tolerant 
mothers, as in the Hyperglycaemia and Adverse Pregnancy Outcome (HAPO) trial, 
which highlighted the importance of maternal plasma glucose concentrations for 
increased birth weight and adiposity in the offspring (5). However, plasma glucose 
concentration did not explain all the variance in offspring adiposity, with residual 
contributions coming from maternal pre-pregnancy BMI and gestational weight gain 
(10-12). Furthermore, increased birth weight is observed even in GDM pregnancies 
in which plasma glucose is well-controlled (10,13,14).  
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There is evidence to suggest that high maternal fat mass and insulin resistance may 
expose the fetus to fuels other than glucose that could contribute to higher birth 
weight (13,15-17). Maternal hypertriglyceridaemia is a key element of maternal 
obesity and insulin resistance (7,8). Whole body lipolysis is increased in the third 
trimester of pregnancy (18) and is associated with maternal fat mass and estimated 
fetal weight (19). Maternal plasma triglyceride and free fatty acid also correlate with 
birth weight and measures of neonatal adiposity in GDM and in women screened for 
GDM with normal glucose tolerance (20-22). However, it is not clear if  these 
relationships exist in healthy non-obese pregnancy, to what extent they are 
independent of maternal body weight, and whether measures of maternal body fat 
distribution may be superior predictors of fetal birth weight and/or adiposity (23).  
Obesity, as defined by BMI in excess of 30, is a universally accepted measure of body 
fatness, but BMI conveys no information about the quantity, quality, location or 
metabolic function of discrete fat depots. BMI is a relatively weak proxy for 
discriminating metabolic dysfunction and cardio-metabolic risk in comparison to 
central obesity, especially when the latter is distinguished by high intra-abdominal 
visceral adipose tissue (VAT)(24).  BMI is unable to distinguish between individuals 
(pregnant or non-pregnant) who store fat as relatively benign subcutaneous adipose 
tissue (SAT) or as VAT, which is intimately associated with insulin resistance, 
hyperglycaemia, hypertriglyceridaemia, metabolic dysfunction and pathology (25-
27).  None of the above studies that related maternal adiposity to offspring 
birthweight and adiposity assessed body fat distribution. 
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In studies of pregnancy that did assess body fat distribution, pre-peritoneal and 
visceral fat were shown to increase during gestation, while SAT declined (28-32). 
Measures of VAT strongly predict metabolic complications of pregnancy, GDM 
(33,34) and pre-eclampsia (35,36), but it is not clear to what extent VAT is directly 
related to insulin resistance and increased plasma lipids and glucose in pregnancy 
(33,37-42). While VAT, measured by ultrasound between 12 and 20 weeks of 
gestation, is associated with fetal growth in overweight and obese women in the first 
trimester (43), with fetal growth and adiposity in the second trimester (44), and 
birthweight (45), the impact of abdominal SAT thickness on these measures has been 
largely overlooked. SAT thickness is correlated with first trimester fetal growth, but 
less so than VAT (43). SAT has also been found to be predictive (46-48) and non-
predictive of GDM (49), and is also less strongly associated with metabolic risk 
factors in pregnancy than VAT (37). 
The aim of this study was to assess the contribution of maternal body fat distribution 
to offspring birth weight and maternal and fetal insulin resistance in order to 
advance our understanding of the consequences of maternal obesity. Maternal first 
trimester measures of adiposity including BMI, VAT, abdominal SAT and hip 
circumference (a biomarker of lower body SAT) were assessed as predictors of birth 
weight, adiposity and metabolic dysfunction in neonates of healthy pregnant 
women. We also determined if any relationship could be explained by the influence 
of these fat depots on maternal glucose and lipid metabolism or placental weight.  
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Methods 
Longitudinal Study of Pregnancy 
Sixty women registered for obstetric care at the Princess Royal Maternity Unit, 
Glasgow, who were healthy and normotensive with no significant past medical 
history were recruited and followed prospectively throughout pregnancy. This study 
was initially designed to assess the impact of maternal obesity on microvascular 
function and powered for that outcome (50). Seven women were excluded from the 
final analysis; three delivered pre-term, two were excluded because of missing birth 
weight data, one had a miscarriage, and one had a baby with diGeorge syndrome.  
All remaining women had no pregnancy-related complications. Baseline data and 
complete longitudinal data were available for 53 and 45 women, respectively.  The 
study was performed according to the Declaration of Helsinki, approval was granted 
by the Research Ethics Committee of North Glasgow University NHS Trust, and each 
subject gave written informed consent. The women attended after an overnight fast 
(>10 hours). Blood samples were collected at a mean of 12.4 (range 8–14) [T1], 26.1 
(24–28) [T2] and 35.5 (33–38) [T3] weeks of gestation. The characteristics of the 
patients were recorded at the first antenatal hospital appointment and delivery 
details from patient notes. Customised birth weight centiles were calculated using 
the Gestation Network Centile Calculator 5.4 
(http://www.gestation.net/birthweight_centiles/centile_online.htm). Deprivation 
category (DEPCAT score), a measure of socioeconomic status, was assigned using the 
Scottish Area Deprivation Index for Scottish postcode sectors, 1998 (51). Placental 
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tissue and fetal cord blood was collected at delivery from a subgroup of these 
pregnancies (n=23, 42%). 
Baseline anthropometric and fat thickness measurements 
At the first antenatal appointment (mean 12.4 weeks of gestation), patient height, 
weight, waist circumference and hip circumference were measured. Waist 
circumference was measured at the level of the umbilicus. Hip circumference was 
measured at the widest point over the buttocks. Waist and hip circumference were 
measured in duplicate to the nearest 0.5 cm. If the difference between the two 
measurements was greater than 2 cm, a third measurement was taken and the mean 
of the two closest measurements was calculated. All measurements were taken by 
the same examiner. Body mass index (BMI) was calculated as booking weight (kg), 
divided by height (m) squared.  Baseline upper body abdominal SAT and upper body 
VAT thickness was assessed by ultrasound (52). Measurements were taken 2cm 
below the xiphisternum and the abdominal probe was placed on the skin with 
minimal pressure. Abdominal SAT was measured as the thickness between the 
inferior border of the dermal layer and the rectus abdominus sheath at the level of 
the umbilicus. Visceral fat was taken as the vertical measurement between the 
rectus sheath and the aorta at the umbilicus. Three consecutive measurements in 
millimetres were taken and an average reading was calculated. All measures were 
made by the same operator (F.S.) on the same machine. 
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Blood parameters 
Glucose assays (53) were performed by Clinical Biochemistry, Glasgow Royal 
Infirmary and plasma total cholesterol, HDL cholesterol and total triglyceride 
concentrations were determined as described previously (7). Insulin (Mercodia) and 
leptin (R & D Systems) analyses were performed by ELISA according to the 
manufacturer’s instructions. LPL mass was determined by ELISA using bovine LPL as 
standard (54,55). HOMA was calculated as [fasting insulin (mU/L) x fasting glucose 
(mmol/L)]/22.5]. Erythrocyte membrane phospholipid fatty acid composition was 
measured as previously described (56), and the ratio of 16:0/18:2 n-6 was used as an 
index of de novo lipogenesis (57,58). 
Statistical analysis 
Continuous variables are represented as means (standard deviation), categorical 
variables as number and percentage. Total area under the time (T1 to T3 weeks’ 
gestation) x concentration curve (AUC) were calculated using the trapezium method 
(59). Normality testing was carried out using the Ryan-Joiner test and data was log or 
square root transformed to achieve a normal distribution as necessary. Associations 
between variables were examined by Pearson’s correlation analysis. Two measures 
of gestational fuel exposure were used. Firstly, the total area under the trimester 1 
to trimester 3 maternal glucose, and triglyceride concentration and HOMA curves 
were calculated to assess total gestational exposure. Secondly, because the 
univariate associations between maternal anthropometrics and maternal plasma 
triglyceride, glucose and HOMA were the strongest and notably distinct in trimester 
2 (Supplemental Figure 1(60)), trimester 2 data were selected for further study.  
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Stepwise regression analysis, a method of fitting regression models in which the 
choice of predictive variables and simultaneous removal of unimportant variables is 
carried out by an automatic procedure, was used to test associations between 
maternal anthropometrics and maternal or fetal blood glucose and lipids and the 
influence of confounding variables such as placental weight, using P-to-enter and P-




Demographic data for all women with first trimester measurements are shown in 
Table 1. Women were on average 28 years of age, had a mean body mass index 
(BMI) of 28 kg/m2; just over one third were currently smoking during their pregnancy 
and just less than one half were in their first pregnancy. More than half the women 
were classed as having deprived social status. The women had normal antenatal 
appointment blood pressure, had no pregnancy-related complications and all 
delivered healthy babies at term. The demographic characteristics of the subgroup, 
where repeated longitudinal measures were available, were similar to the total 
group (Table 1). 
Relationship between maternal anthropometrics and offspring birth weight centile 
and placental weight 
Maternal BMI is a recognised predictor of offspring birthweight. To test whether 
other, more specific, measures of maternal adiposity might be better predictors of 
offspring birth weight, univariate correlation between maternal anthropometric 
measures and birth weight centile, birth weight and placental weight were first 
assessed. Birth weight centile was associated with maternal BMI (r=0.41, P=0.002), 
waist circumference (r=0.42, P=0.003), hip circumference (r=0.32, P=0.021), SAT 
thickness (r=0.34, P=0.012), VAT thickness (r=0.41, P=0.003) and SAT plus VAT 
thickness (r=0.39, P=0.004), but not waist-hip ratio (r= 0.16, P=0.25) or VAT/SAT ratio 
(r=0.01, P=0.97). No maternal anthropometric measures were associated with birth 
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weight alone, and only maternal BMI was weakly associated with placental weight 
(r=0.27, P=0.047).  
To examine possible multivariable associations between maternal anthropometrics 
and birth weight centile, the former was entered into a stepwise regression model (P 
to enter and P to stay 0.15).  VAT was the only anthropometric measure significantly 
associated with birth weight centile (r2 adjusted 15.8%, P=0.002, Figure 1). A one mm 
increase in VAT thickness resulted in a 2.26 centile increase in birthweight centile. A 
VAT thickness of up to 10mm was associated with the 43rd (unadjusted) and 38th 
(after adjustment for BMI, waist circumference, hip circumference, SAT thickness 
and SAT plus VAT thickness) birth weight centile. Above 10mm VAT, birth weight 
centiles were between the 70th and 80th centile. While inclusion of placental weight 
in the regression model attenuated the relationship between VAT and birth weight 
centile, it remained significant [r2 adjusted 11.8%, P=0.006; birth weight centile = -
12.3 + 1.891 VAT (mm) + 0.0630 placental weight (g)] suggesting an independent 
association between VAT thickness and birth weight centile. Placental weight was 
significantly associated with birth weight centile in this model (r2 adjusted 12.1%, 
P=0.005), suggesting that placental weight also has an independent contribution to 
birth weight equivalent to that of VAT thickness. 
Relationships between maternal anthropometrics and fetal cord plasma glucose and 
lipids  
In a univariate analysis maternal VAT thickness was significantly correlated (P<0.05) 
with fetal cord plasma total cholesterol, triglyceride, non-esterified fatty acids and 
negatively with a marker of insulin resistance (HOMA), but there was no relationship 
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with fetal cord plasma HDL cholesterol, glucose or insulin (Table 2). Maternal SAT 
thickness correlated significantly with cord plasma total cholesterol. There was no 
relationship between maternal BMI or hip circumference and cord plasma glucose or 
lipids. On multivariate regression analysis, VAT showed significant independent 
associations with cord plasma triglyceride, non-esterified fatty acids and cholesterol, 
while BMI showed significant negative independent associations with cord plasma 
insulin and HOMA (Table 2). After inclusion of mode of delivery in the model, the 
associations between maternal BMI and cord plasma insulin and HOMA and 
between VAT and cord plasma triglyceride persisted and now hip circumference was 
positively associated with cord plasma cholesterol (Table 2). The inclusion of 
placental weight in the regression model had no impact on the associations between 
BMI and cord plasma HOMA, VAT thickness and cord plasma triglyceride or between 
hip circumference and cord plasma cholesterol maternal BMI and HOMA.  The 
inclusion of placental weight strengthened the negative association between BMI 
and cord blood insulin (r2 adjusted 31%, P=0.009).   
Relationship between maternal anthropometrics and maternal plasma glucose and 
lipids  
Maternal BMI was correlated significantly (P<0.05) with maternal trimester 2 and 
AUC glucose and trimester 2 and AUC HOMA (Table 3). SAT thickness was correlated 
significantly with maternal trimester 2 HOMA only. VAT thickness was correlated 
with maternal trimester 2 glucose and HOMA. Hip circumference was correlated 
with maternal AUC glucose and trimester 2 and AUC HOMA.  On stepwise regression, 
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only maternal BMI remained significantly associated with both maternal trimester 2 
and AUC glucose and HOMA (Table 3).  
Relationships between maternal plasma glucose and lipid exposure and fetal cord 
plasma glucose and lipids, fetal adiposity (cord plasma leptin) and birth weight 
centile  
None of the markers of maternal glucose or lipid gestational exposure were 
associated with any measure of cord plasma glucose or lipid metabolism or fetal 
adiposity before or after accounting for mode of delivery other than maternal AUC 
triglyceride (r2 = 20%, P=0.020, coefficient = -0.007) and maternal AUC HOMA 
(r2=15%, P=0.042, coefficient = 0.255) which were associated with cord plasma HDL 
after accounting for mode of delivery. Maternal trimester 2 HOMA (r=0.33, P=0.028) 
and AUC glucose (r=0.36, P=0.016) were univariately associated with birthweight 
centile. T2 HOMA (P=0.046) and placental weight (P<0.001) remained as predictors 
of birthweight centile in a minimal model that included these two variables and AUC 
glucose (r2 adjusted =31.7%).  
Maternal anthropometric measures and fetal adiposity  
Fetal adiposity was not associated with maternal BMI, SAT or VAT thickness or hip 
circumference in multivariate analysis. However, there was a significant positive 
association between placental weight and cord plasma leptin (r2=57%, P<0.001). A 
multivariable model including maternal anthropometrics, placental weight and mode 
of delivery showed that only placental weight was independently associated with 
fetal adiposity (r2 adjusted 48%, P<0.001). There was no association between cord 
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plasma triglyceride or non-esterified fatty acids and fetal adiposity even after 
adjusting for mode of delivery. The 16:0/18:2 n-6 ratio of fetal erythrocyte fatty acids 
was used as an index of de novo lipogenesis. This index was unrelated to fetal 
adiposity (r=-0.13, P=0.57), but inversely associated with fetal cord plasma 
triglyceride (r=-0.44, P=0.044) (Supplemental Figure 2 (60)), an effect lost after 
accounting for mode of delivery. 
Maternal lipoprotein lipase (LPL) mass, maternal and fetal plasma glucose and lipids, 
fetal adiposity and birth weight centile  
Low LPL mass is a marker of severity of metabolic syndrome and low plasma levels 
reflect reduced LPL synthesis by adipocytes in the insulin resistant state. Maternal 
trimester 2 LPL mass was negatively correlated with maternal BMI (r=-0.36, P=0.017) 
and SAT (r=-0.36, P=0.018) while AUC LPL mass correlated with SAT (r=-0.30, 
P=0.048). In a multivariate regression model including all maternal anthropometrics, 
maternal SAT alone predicted trimester 2 LPL mass (r2 adjusted 11.3%, P=0.017).  
Maternal trimester 2 or AUC LPL mass was not correlated with cord plasma glucose 
or lipid levels. Maternal trimester 2 LPL was negatively correlated with maternal 
trimester 2 glucose (r=-0.30, P=0.049), AUC glucose (r=-0.36, P=0.019) and trimester 
2 HOMA (-0.30, P=0.048). In particular, maternal trimester 2 and AUC LPL mass were 
strongly correlated with maternal trimester 2 triglycerides (r=-0.52, P=0.001 and r=-
0.55, P<0.001 respectively) and AUC triglycerides (r=-0.41, P=0.007 and r=-0.41, 
P=0.006 respectively). Maternal trimester 2 and AUC LPL were not associated with 
birth weight centile but both were strongly associated with fetal leptin (r=-0.69, 
17 
P=0.001 and r=-0.58, P=0.006 respectively) (Figure 2) and these associations were 
independent of mode of delivery. 
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Discussion 
Maternal first trimester VAT thickness on ultrasound, but not first trimester BMI, 
abdominal SAT or hip circumference, was independently associated with birth 
weight centile. This observation is in agreement with a similar study in adolescent 
mothers, although the previous study lacked SAT assessment (45). The strength of 
associations in the current study were of greater magnitude than that previously 
reported, possibly due to our older, more obese population. Maternal VAT was also 
associated with fetal cord plasma triglyceride although the latter variable was 
unrelated to birth weight centile or fetal adiposity. Maternal VAT was not associated 
with maternal plasma lipids, as might be expected from data in non-pregnant 
women, in which an oversupply of fatty acids in the portal circulation to the liver can 
drive an increased  synthesis and secretion of VLDL (61). This lack of relationship 
between maternal VAT and plasma triglyceride suggests that VAT-associated 
hypertriglyceridaemia may be superseded by maternal metabolic adaptation to 
pregnancy.  
We have previously shown in ex vivo adipocyte lipolysis experiments, that SAT 
adipocytes have higher lipolysis rates than VAT adipocytes in pregnancy (62). Thus, in 
healthy pregnancy, SAT rather than VAT is the primary source of the maternal fatty 
acids released for maternal metabolism and placental transport, secondary to 
pregnancy hormone induced gestational insulin resistance (62).  A slowing or 
reversal of maternal (subcutaneous) adipose tissue accumulation towards the end of 
the second trimester coincides with the accelerated phase of fetal adipose tissue 
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accretion (14).  In pregnancy, it is possible that VAT is a marker of ectopic fat 
accumulation rather than a direct source of lipids for transport to the fetus. In non-
pregnant individuals, fat accumulation in VAT and ectopically in other organs is 
secondary to dysregulated adipocyte expansion in subcutaneous fat (24,63,64). Fatty 
acids that overspill from the SAT compartment accumulate in VAT and are stored 
ectopically as intracellular lipid droplets in other tissues such as the liver and 
pancreas. However, in pregnancy, the overspill fatty acids from SAT could also be 
available for uptake and transport by the placenta, thus increasing lipid supply to the 
fetus (Figure 3).  
Low maternal LPL mass is a measure of metabolic syndrome severity and probably 
reflects a reduced rate of LPL synthesis by insulin resistant SAT adipocytes (7,65-67). 
In the present study, LPL mass was inversely associated with maternal plasma 
triglyceride and fetal adiposity, supporting the idea of a failure of SAT adipocyte 
expansion and the development of adipocyte insulin resistance with a consequent 
overspill of fatty acids and transport to the fetus (Figure 3). Potential mechanisms for 
increased fetal adiposity include an increased lipid supply across the placenta or 
increased de novo lipogenesis from glucose supplied across the placenta. The inverse 
association between cord plasma triglyceride and an index of fetal de novo 
lipogenesis was not independent of mode of delivery, and in any case would suggest 
that the transported fatty acids may be utilised by the fetus in preference to the de 
novo synthesis of fatty acids. Failure of SAT adipocyte expansion has been proposed 
to underlie obesity-related pre-eclampsia (62) and gestational diabetes mellitus 
(68,69). In the healthy women under study here, the maximum VAT thickness 
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measured was 27.3mm, which may represent a propensity towards limited SAT 
expansion rather than a pathological state, especially when it is considered that 
preliminary studies indicated that pre-eclampsia and GDM are predicted by VAT 
thickness above 52mm (36) and 47.4mm (33) respectively. Assessment of VAT 
thickness in larger populations would be useful to assess its ability to predict similar 
adverse pregnancy outcomes. 
Maternal placental weight had an independent association with birth weight centile 
in this cohort of women. Maternal body mass index was related to both placental 
weight and maternal insulin resistance, and through these associations may be 
indirectly linked to birth weight centile and fetal adiposity. Our data showed that 
trimester 2 markers of glucose metabolism were most strongly related to maternal 
anthropometrics. The middle trimester is the time of greatest acceleration in fetal 
growth (70), when changes in maternal metabolism would be expected to have most 
impact on birthweight centile. Maternal gestational insulin resistance directs more 
glucose for transport to the fetus. A combination of higher placental weight, 
increased surface area for transport of nutrients, and raised trimester 2 plasma 
glucose may explain the link between BMI and fetal birth weight centile and 
adiposity. Interestingly, maternal BMI was associated with reduced fetal cord blood 
insulin and HOMA suggesting that in the present study fetuses of healthy high BMI 
mothers are more insulin sensitive and hence efficient at storing fuel as adipose 
tissue in addition to having more insulin-induced somatic growth. However, this 
could be due to our small sample size and limited statistical ability to account for 
confounders. Previous larger studies (5,71) show a positive relationship between 
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maternal BMI and cord blood insulin suggesting that Pedersen’s hypothesis also 
applies in healthy normoglycaemic pregnancies. It is currently not clear to what 
extent fetal insulin sensitivity is directly influenced by the mother or is a fetal 
response to the availability of fuel.  
The data presented here suggest an input from both glucose and lipids into birth 
weight and fetal adiposity. While there is plentiful evidence to link maternal plasma 
glucose levels with fetal growth, there has been less research into the role of plasma 
lipids. Lipid concentrations are equally regulated by insulin and affected by insulin 
resistance. It is notable that a stable isotope tracer study in healthy women at 34-36 
weeks of gestation showed that both glucose production rate and lipolysis were 
independently correlated with estimated fetal size on ultrasound scan (19). Our data 
also suggest that glucose and lipid metabolism are intertwined and influenced by 
both maternal adiposity and body fat distribution. 
This study had a number of strengths including its prospective design and the 
assessment of a number of maternal anthropometrics in parallel with measures of 
both maternal and fetal cord glucose and lipid metabolism. Limitations include a lack 
of kinetic assessment of maternal and fetal metabolites and the use of steady state 
concentrations to infer such fluxes. Our conclusions with respect to fetal adiposity 
are limited by cord blood samples being collected in less than half of the cohort (23 
pregnancies), in which plasma leptin concentration was measured as a surrogate. In 
addition, cord plasma measurements may have been confounded by a number of 
pregnancy factors including fetal sex, mode of delivery, gestational age and maternal 
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fasting status at delivery and maternal smoking, statistical adjustment for which may 
have been inadequate 
In summary, maternal body fat distribution in healthy pregnancy, as identified by 
VAT thickness, provides additional information to that of maternal BMI in the 
prediction of birth weight centile. VAT may be acting as a marker of reduced SAT 
expansion, leading to increased availability of plasma fatty acids for placental 
transport. The data do not address the clinical value of measuring SAT and VAT over 
BMI as ultimately the data do not directly link either SAT or VAT to any adverse 
maternal or fetal pregnancy outcome. Instead the data suggest that the ability of a 
woman to expand her SAT depot in response to pregnancy hyperphagia may predict 
her metabolic response and ultimately her susceptibility to metabolic complications 
of pregnancy, such as pre-eclampsia and GDM, and her offspring’s propensity to 
adiposity, at least at birth. As to what is the best marker of this susceptibility e.g. VAT 
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Legends for figures and tables 
Figure 1. Offspring birth weight centile by VAT thickness: 0-10mm [n=19, mean 
(standard deviation) 7.5 (2.0) mm], 10-20mm [n=27, 15.0 (2.6) mm], 20-30mm [n=7, 
22.9 (2.9) mm]. Means and 95% confidence interval for the mean are plotted for 
unadjusted data and data adjusted for other anthropometric measures in a stepwise 
regression (BMI, waist circumference, hip circumference, SAT thickness, SAT plus 
VAT thickness). 
Figure 2. Association between fetal adiposity (cord plasma leptin) and maternal 
trimester 2 lipoprotein lipase mass. Univariate correlation (Pearson’s) between 
maternal trimester 2 lipoprotein lipase mass and fetal adiposity r=-0.69 P=0 .001 
(n=2 data missing). 
Figure 3. Proposed pathway for the contribution of maternal BMI, SAT and VAT to 
fetal birth weight and adiposity. In low BMI pregnant women subcutaneous 
adipose tissue (SAT) contains insulin sensitive (IS), hyperplasic adipocytes 
secreting large amounts of lipoprotein lipase (LPL) that are capable of 
expanding to store excess fatty acids (NEFA). In an insulin sensitive 
environment, this facilitates regulation of maternal glucose and triglyceride 
concentrations providing sufficient fuels for placental transport to support 
healthy fetal growth. In high BMI pregnant women, SAT contains insulin 
resistant (IR), hypertrophic adipocytes resulting from limited expansion of 
pre-adipocytes to form mature adipocytes. SAT has a reduced ability to store 
fatty acid which spill over and are directed to the liver increasing plasma 
triglyceride (TG) concentrations and are stored ectopically in visceral adipose 
tissue (VAT). The increasingly insulin resistance environment also raises 
plasma glucose levels thus increasing the supply of both fuels across a larger 
placenta resulting in a larger and fatter fetus. 
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Table 1. Maternal antenatal booking characteristics. Values are mean and standard 






Cord blood data 
n=23 
Booking visit 
Age (years) 28.3 (5.1) 28.6 (5.0) 28.9 (4.6) 
Smokers (number (%)) 19 (35.8) 16 (35.6) 8 (34.8) 
Deprivation Index  













Primiparous 25 (47.2) 21 (46.7) 12 (52.2) 
Systolic Blood Pressure (mmHg)  118 (13) 119 (11) 118 (12) 
Diastolic Blood Pressure (mmHg)  68 (9) 69 (9) 68 (9) 
BMI (kg/m2) 28.4 (6.0) 28.1 (5.7) 26.6 (5.7) 
BMI range (kg/m2) 18.0 – 46.3 18.0 – 46.3 19.0 – 46.3 
Waist circumference (cm) 89.5 (14.8) 89.5 (14.8) 84.3 (11.4) 
Hip circumference (cm) † 107 (15) 108 (15) 104 (15) 
Waist/Hip ratio 0.83 (0.08) 0.84 (0.08) 0.81 (0.07) 
Visceral fat thickness (mm) 13.4 (5.6) 13.2 (5.5) 12.1 (5.8) 
Subcutaneous fat thickness (mm) 25.1 (11.4) 24.5 (10.9) 22.9 (11.0) 
Visceral/Subcutaneous fat thickness 0.58 (0.23) 0.58 (0.24) 0.58 (0.27) 
Visceral plus subcutaneous fat 
thickness (mm) 
38.4 (15.7) 37.7 (15.1) 35.0 (15.2) 
At delivery 
Gestation at delivery (days) 279 (9) 281 (7) 278 (8) 
Fetal sex, number (%) male 29 (55) 24 (53) 15 (65) 
Placental weight (g)  763 (175) 785 (175) 788 (193) 
Birth weight (g)  3606 (555) 3680 (560) 3675 (628) 
Birth Weight Centile 
Mode of delivery (number %) 
61 (31) 62 (31) 58.8 (34) 
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 Assisted 
 Elective Caesarean section 
 Emergency Caesarean section 














Table 2 Maternal BMI, VAT thickness, SAT thickness and hip circumference association with fetal cord plasma markers of glucose and lipid metabolism 
Mean (standard deviation) cord plasma levels (n=23) of each parameter are shown below along with their univariate association (Pearson’s correlation) 
with maternal BMI, VAT and SAT thickness and hip circumference. The relationship between maternal BMI, VAT and SAT thickness and fetal cord plasma 
metabolic measures was determined by entering BMI, SAT, VAT and hip circumference in a stepwise regression model P to enter and P to stay 0.15. Mode 
of delivery (MOD) [assisted (A), elective Caesarean section (L), emergency Caesarean section (M) and vaginal (V) delivery] was added to the models as a 
confounding variable. NEFA = non-esterified fatty acid.  r2 adjusted and P values are stated. *analysis carried out on log-transformed data. † P<0.05, ‡ no 
terms were at P<0.15 to be entered into the model.  

























-0.0655 VAT 6.9% 0.013 No model‡ - 
Insulin* 
(mU/L) 








-0.0332 BMI 15.4% 0.040 BMI 15.4% 0.040 
HOMA-IR* 1.29 (1.21) BMI -0.38 -0.0596 BMI 20.5% 0.023 BMI 20.5% 0.023 
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0.01994 VAT 14.8% 0.043 VAT 9.3% 0.047 
NEFA* 
(mmol/L) 
































No model‡ - -
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Table 3 Maternal BMI, abdominal visceral and subcutaneous adipose tissue and hip 
circumference associations with maternal markers of gestational fuel exposure Mean 
(standard deviation) maternal plasma trimester 2 levels or AUC trimester 1 to trimester 3 
(n=45) are shown below along with their univariate association (Pearson’s correlation) with 
maternal BMI, VAT and SAT thickness and hip circumference.  
The relationship between maternal BMI, visceral adipose tissue (VAT) and upper body 
subcutaneous adipose tissue (SAT) thickness and maternal plasma metabolic measures was 
determined by entering BMI, SAT, VAT and hip circumference in a stepwise regression model 
P to enter and P to stay 0.15. r2 adjusted and P values are stated. *analysis carried out on 



































0.00348 SAT 5.1% 0.078 
Maternal T2 
HOMA* 


























































weeks)* Hip 0.31† 
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Figure 3 
